CD8A and neoplasm: Likewise, mesoporous silica vectors carrying tyrosinase-related peptides and TLR agonists were effectively used by Zhu et al. [155] to enhance dendritic cell activation and tumor-specific CD8+ T cell responses to tumor immunotherapy.